Table 1.
The characteristics of participant population.
Figure 1.
The use of serum CCSA-2 to detect CRC.
(A) Comparison of serum CCSA-2 levels in colorectal cancer patients and other individual groups. *: the serum CCSA-2 concentration in CRC patients was significantly higher than each of the other individual groups(P<0.01); **,#,##,+,++,@: there were no statistical significances between other couple groups (P>0.05). (B) Receiver operator characteristic (ROC) curve for serum CCSA-2 in separating colorectal cancer patients and other individuals. CRC: colorectal cancer; GC: gastric cancer; BC: breast cancer; IH: inguinal hernia; AA: acute appendicitis; HD: healthy donor; BD: benign disease.
Table 2.
CCSA-2 expression in different tumor stages and different tumor grades.
Table 3.
Specificity/Sensitivity of Serum CCSA-2 Assay.
Table 4.
Compared the use of CCSA-2 with CEA or CA19-9 to detect colorectal cancer.
Figure 2.
Pre- and post-operative levels of serum CCSA-2 in colorectal cancer patients.
*,#: Statistic analysis showed the serum CCSA-2 concentration decreased significantly after surgery, but is still higher than the level of negative control (F = 827.57, P<0.001).
Figure 3.
The use of serum CCSA-2 as a surveillance and prognostic marker for CRC.
(A) Serum CCSA-2 levels in pre-operation, post-operation and after recurrences in patients who suffered relapse during the follow-up period. *:the serum CCSA-2 concentration in pre-operation was significantly higher than each of the other individual groups (P<0.01); #: the serum CCSA-2 levels after recurrences was higher than that in post-operation (P<0.01). (B) Comparison of pre-operative serum CCSA-2 levels in patients with recurrences and without recurrences during the follow-up period after surgery. *: Statistic analysis showed the pre-operative serum CCSA-2 concentration in patients with recurrences was significantly higher than those in patients without recurrences after surgery (t = 6.18, P<0.001).